about
The effect of cross-sex hormonal treatment on gender dysphoria individuals' mental health: a systematic reviewDoes Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human CognitionEffect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence.Functional genetic variation of the cannabinoid receptor 1 and cannabis use interact on prefrontal connectivity and related working memory behavior.Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis.Interaction between DRD2 and AKT1 genetic variations on risk of psychosis in cannabis users: a case-control studyTo treat or not to treat: puberty suppression in childhood-onset gender dysphoria.Substance use, medication adherence and outcome one year following a first episode of psychosis.Transsexual patients' psychiatric comorbidity and positive effect of cross-sex hormonal treatment on mental health: results from a longitudinal study.Attachment styles in transsexual patients and clinical and nonclinical control groups: a response.Associations between psychosis endophenotypes across brain functional, structural, and cognitive domains.Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study.Hormonal treatment reduces psychobiological distress in gender identity disorder, independently of the attachment style.Dissociative symptoms in individuals with gender dysphoria: is the elevated prevalence real?Prefrontal activity during working memory is modulated by the interaction of variation in CB1 and COX2 coding genes and correlates with frequency of cannabis use.Concomitant psychiatric problems and hormonal treatment induced metabolic syndrome in gender dysphoria individuals: a 2 year follow-up study.Psychological Support, Puberty Suppression, and Psychosocial Functioning in Adolescents with Gender Dysphoria.Hyperprolactinaemia in first episode psychosis - A longitudinal assessment.S224. DELTA-9-TETRAHYDROCANNABINOL CHALLENGE IN CANNABIS USERS AND NON-USERS DIFFERENTIALLY AFFECTS BRAIN FUNCTION AND BEHAVIOR: AN FMRI STUDY OF DEVELOPMENT OF TOLERANCE.F68. PREMORBID IQ, EDUCATIONAL LEVEL AND JUMPING TO CONCLUSIONS AS PREDICTORS OF CLINICAL OUTCOME AT FIRST ONSET OF PSYCHOSIS OVER THE NEXT 4 YEARS: THE GAP STUDY.S152. CANNABIDIOL INDUCED MODULATION OF MEDIOTEMPORAL ACTIVITY DURING A VERBAL MEMORY TASK IN FIRST-EPISODE PSYCHOSIS.Longitudinal assessment of the effect of cannabis use on hospital readmission rates in early psychosis: A 6-year follow-up in an inpatient cohortModulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposurePrevious cannabis exposure modulates the acute effects of delta-9-tetrahydrocannabinol on attentional salience and fear processingJumping to conclusions at first onset of psychosis predicts longer admissions, more compulsory admissions and police involvement over the next 4 years: the GAP studyInteraction between childhood adversity and functional polymorphisms in the dopamine pathway on first-episode psychosisThe Neural Substrate of Reward Anticipation in Health: A Meta-Analysis of fMRI Findings in the Monetary Incentive Delay Task.Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosisCannabis and psychosis: what do we know and what should we do?The influence of risk factors on the onset and outcome of psychosis: What we learned from the GAP studyShould we be concerned about stigma and discrimination in people at risk for psychosis? A systematic reviewCannabis and Cognition: Connecting the Dots towards the Understanding of the RelationshipCannabis use and the development of tolerance: a systematic review of human evidencePrevention and early intervention in youth mental health: is it time for a multidisciplinary and trans-diagnostic model for care?The 2019 Schizophrenia International Research Society Conference, 10-14 April, Orlando, Florida: A summary of topics and trendsDescriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in HumansMedically unexplained symptoms in the times of Covid-19 pandemic: a case-reportAssociation of cannabis with glutamatergic levels in patients with early psychosis: Evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosisDifferential gene expression analysis in blood of first episode psychosis patientsEffects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis
P50
Q26740930-019C6585-158B-41F6-8B46-5AB1C58736F0Q33700887-A9D0A915-ADAA-44AF-BF40-79A6391AE1DEQ34518668-4C1572B2-EB46-4E29-A1A8-A4AD43D58012Q34906834-9289F115-A3A7-4760-83D0-5FFA54A969B4Q35950814-D84675F8-098B-43E8-A5AC-FF2CF338B987Q36848298-0CB44BF8-6971-4D52-A49B-710701770C96Q38901436-7B747E49-13DC-485D-ABCD-4C3C9E6621A4Q40157599-CF4E0F36-43D7-43C9-9E34-E6FAA9C2362BQ43781509-C500F6D7-73DB-4E58-AD3A-D121C99C2D49Q45420473-1E747797-F429-4AA2-8E30-71A678A0232FQ47583502-508777D7-0BB0-49EC-A429-A2F81CF052E8Q47702704-FC3DC318-A539-487B-9DA3-4ABCBB650601Q48031053-DDA34C6F-8AB7-4DE9-B3CF-CF4BFC3C5758Q48120887-A6EAA17B-628A-4B69-814A-A3AEF74C2DEDQ48694806-304463FD-F444-4C82-A401-628561774B40Q50596838-CCB1E179-B061-4BF3-A9A9-D55037421973Q52146956-41E3078C-D317-423F-89FE-3153D3004294Q53101828-176DFF2F-83D9-4388-A76D-6CE04AB7665BQ54964304-F169BD7A-AFE4-417B-8271-407DDC6FB155Q55260087-2265640F-961C-4F69-9C9E-4DC6480F148BQ55447961-CEB6981C-954A-4C7F-A6EA-43196351711DQ56350249-662978EC-6305-4F04-AAD6-36EEA111254EQ57978106-1CF1E42E-ABE7-4BE9-AD11-1480EEFCC0CBQ60242671-36A5693D-7BA5-4507-A820-FD43FC718349Q60393177-E57D36A8-9ADB-49B9-A801-310104683A70Q60440948-D29A286A-864F-423A-8840-44C060DA1F61Q60630987-AAD4ED67-A6A3-48BC-A640-50C42DB7026DQ62725703-63C04F73-A737-46B7-AB17-02F38FF4E570Q88107906-A54E8AE6-F1E9-4BF4-8923-EC972FDD48D3Q89615490-A67BF86F-5C10-4979-8F48-19AF2FB64D58Q89734046-17516F0A-1BFA-4964-AC2D-BC410FA876E4Q89975548-B7B90670-F602-450B-B135-393E42FE8439Q90591235-796804C8-0A3E-4BDB-8C40-226ADBB41B70Q90745993-0381E630-0B7A-4818-B75A-A2707938CF8FQ91521955-14111051-2DE4-4D3C-8607-04D2EA46CF91Q91549455-F9D207F4-57EE-46EE-938F-D5EEF1449B94Q92103422-6AAAAFFC-168D-474C-BCC4-2E03E333165BQ92130252-B27FF8E5-EF8B-45A0-B66B-2A3F8F52FD33Q92197348-8BF0C011-9493-4971-8A91-844604982470Q92506685-971C2711-017D-4132-B80B-C99C10FEF6B7
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marco Colizzi
@ast
Marco Colizzi
@en
Marco Colizzi
@es
Marco Colizzi
@nl
Marco Colizzi
@sl
type
label
Marco Colizzi
@ast
Marco Colizzi
@en
Marco Colizzi
@es
Marco Colizzi
@nl
Marco Colizzi
@sl
prefLabel
Marco Colizzi
@ast
Marco Colizzi
@en
Marco Colizzi
@es
Marco Colizzi
@nl
Marco Colizzi
@sl
P1053
K-3449-2016
P106
P1153
56299892600
P21
P31
P3829
P496
0000-0001-6139-1920
P569
2000-01-01T00:00:00Z